Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
We produce useful and usable guidance for the NHS and wider health and care system.
Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Latest from NICE
New drug approved for inherited clotting disorder, offering simpler dosing and enhanced quality of life.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
Harnessing expertise to improve patient access to innovative health technologies
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
NICE’s prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Implementation and planning
Best practice resources for practitioners and commissioners.
More ways we support you
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
How NICE makes its decisions
NICE 25: What are our future challenges and opportunities?
On NICE’s 25th anniversary, our partners and collaborators in the health care system discuss what the future holds for NICE.